Navigation Links
Sonic Hedgehog variations linked to recurrence, survival and response to therapy of bladder cancer

HOUSTON - Genetic variations in the Sonic Hedgehog pathway increase the likelihood of recurrence, reduce survival time and limit response to therapy for people with non-muscle invasive bladder cancer, scientists from The University of Texas M. D. Anderson Cancer Center reported today at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference.

"These variations are strongly associated with response to standard immunotherapy that patients receive after tumor resection," said senior author Xifeng Wu, M.D. Ph.D., professor in M. D. Anderson's Department of Epidemiology. "Discovering the genetic aspects of bladder cancer risk is another step toward personalized cancer therapy. We are combining genetic and epidemiological information to build a model that predicts bladder cancer risk and helps guide treatment in the clinic."

Patients who had zero or one of five GLI3 variations associated with response to the Bacillus Calmette-Guerin (BCG) immunotherapy to prevent recurrence had a mean recurrence-free survival time of 114.7 months compared with 9.9 months for those with two-to-five variations.

The Sonic Hedgehog cell signaling pathway plays an important role in embryonic development and stem cell maintenance.

"Abnormal activation of this pathway has been implicated in development of various cancers and progression to metastasis, so we hypothesized that genetic variations might affect bladder cancer patients' clinical outcomes," said Meng Chen, Ph.D., the study's first author.

The team evaluated 494 non-muscle invasive bladder cancer patients for 151 single nucleotide polymorphisms - variations of a single DNA building block in a gene - in nine genes in the pathway.

Patients with non-muscle invasive disease comprise 70-80 percent of all bladder cancer cases. They have a high recurrence rate, at 70 percent, but only 10-15 percent have their disease progress to the invasive stage.

The researchers found a variation in the GLI2 gene that was associated with a doubling of risk of recurrence. Patients with the variation had recurrence-free median survival time of 7.6 months compared to 16.7 months for those without the variation.

Five variations of the GLI3 gene produced the strong response to BCG immunotherapy.

There were no significant effects found in an analysis of 319 patients with invasive-muscle disease.


Contact: Scott Merville
University of Texas M. D. Anderson Cancer Center

Related medicine news :

1. Ultrasonic Cleaner from Tovatech Plays Key Role in World Health Organization's Guidelines for Infection Control
2. VisualSonics Appoints New President and CEO
3. Brooke Burke Debuts Limited Edition Couture Clarisonic on Ultimate Style Stage: The SGK Pink Dress Runway at New York Fashion Week
4. Misonix Expands Sales Organization for Direct Sales of the SonicOne(TM) Wound Management System and the SonaStar(R) Ultrasonic Surgical Aspirator in the United States
5. Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush
6. Sonic Innovations Awarded Contract From U.S. Veterans Administration
7. Otix Global, Inc. to Become Parent Company of Sonic Innovations, Inc.
8. Clarisonic Pounds the Pavement Pink Offering Generous Donation at 2009 Entertainment Industry Foundation Revlon Run/Walk for Women
9. Misonix Announces the Sale of Its Ultrasonic Laboratory Business for $3.5 Million to iSonix LLC
10. Sonic Innovations Celebrates Companys First Receiver-In-Canal Hearing Aid
11. SonicWALL Delivers Flexible High-Performance Threat Management for ZirMed
Post Your Comments:
Related Image:
Sonic Hedgehog variations linked to recurrence, survival and response to therapy of bladder cancer
(Date:10/13/2015)... ... October 13, 2015 , ... ... of a new PDF automation tool to batch conversions of CAD drawings, ... with 100% document fidelity. , CADConverter eliminates the complexity requirement of specialized applications ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... and development solutions for drugs, biologics, consumer health and animal health products, today ... and will lead a new, dedicated global team of drug development and technology ...
(Date:10/12/2015)... ... October 13, 2015 , ... North American Tool Corporation has ... 2015 IBC National Meeting in Rosemont, IL on October 4th. , ... standards of excellence that customers have come to expect from members of IBC’s marketing ...
(Date:10/12/2015)... ... , ... Amerec , a leader in the steam and sauna industry, ... be displaying custom sauna and steam room solutions at the ISPA Conference & Expo ... customers, SpaEquip is recognized for their ability to assist in the design and implementation ...
(Date:10/12/2015)... AL (PRWEB) , ... October 12, 2015 , ... American ... continues to expand its footprint by opening its 151st medical center. Located at 606A ... , “We’re excited to continue fulfilling our mission of making quality health care ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015  Asterias Biotherapeutics, ... with the UK-based Cell Therapy Catapult to advance ... Asterias, allogeneic dendritic cell immunotherapy. Under the agreement, ... manufacturing processes for AST-VAC2 to support advanced clinical ... --> --> The Cell ...
(Date:10/12/2015)... , Oct. 12, 2015 Given ... it is quite challenging to deliver an ophthalmic drug effectively ... overcome for a successful ocular drug delivery. These include dilution ... the lymphatic system of conjunctiva and drug permeation issues with ... the drug, in topical eye drops, is lost due to ...
(Date:10/12/2015)... Use this report to: - Learn about ... medical membrane devices market. - Analyze the present and ... membrane devices market including hemodialyzers, membrane oxygenators, intravenous infusion ... - Gain information on newly approved products, recalls and ... this report to: - Learn about the performance, the ...
Breaking Medicine Technology: